Financial Survey: Alnylam Pharmaceuticals (ALNY) versus Its Peers

Alnylam Pharmaceuticals (NASDAQ: ALNY) is one of 185 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Alnylam Pharmaceuticals to similar businesses based on the strength of its earnings, dividends, profitability, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for Alnylam Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals 3 3 14 1 2.62
Alnylam Pharmaceuticals Competitors 572 2469 6655 133 2.65

Alnylam Pharmaceuticals presently has a consensus price target of $128.65, suggesting a potential upside of 0.47%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.29%. Given Alnylam Pharmaceuticals’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Alnylam Pharmaceuticals and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alnylam Pharmaceuticals $47.16 million -$410.10 million -24.39
Alnylam Pharmaceuticals Competitors $217.40 million -$39.40 million -49.67

Alnylam Pharmaceuticals’ rivals have higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Alnylam Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals -664.70% -46.94% -35.58%
Alnylam Pharmaceuticals Competitors -4,633.05% -35.23% -43.44%

Volatility & Risk

Alnylam Pharmaceuticals has a beta of 2.98, indicating that its stock price is 198% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals’ rivals have a beta of 1.48, indicating that their average stock price is 48% more volatile than the S&P 500.

Insider & Institutional Ownership

88.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.3% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


Alnylam Pharmaceuticals rivals beat Alnylam Pharmaceuticals on 7 of the 13 factors compared.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply